129 results on '"Ackermann, Elizabeth"'
Search Results
2. Questioning the “Melting Pot”: Analysis of Alu Inserts in Three Population Samples from Uruguay
3. Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial
4. Phase 1/2 Trial Evaluating AOC 1044 in Healthy Volunteers and Participants with DMD Mutations Amenable to Exon 44 Skipping (DMD44): EXPLORE44 Trial Design (P4-8.007)
5. Genetic Admixture Analysis in the Population of Tacuarembó-Uruguay Using Alu Insertions
6. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
7. Kind and distribution of cutaneous sensation loss in hereditary transthyretin amyloidosis with polyneuropathy
8. Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of AOC 1020 Administered Intravenously to Adult Patients with Facioscapulohumeral Muscular Dystrophy (FORTITUDE) Trial Design (P3-8.007)
9. DNA polymorphisms associated with lactase persistence, self‐perceived symptoms of lactose intolerance, milk and dairy consumption, and ancestry, in the Uruguayan population
10. Inhibition of Macrophage Ca2+-independent Phospholipase A2 by Bromoenol Lactone and Trifluoromethyl Ketones (∗)
11. Study Design of AOC 1001-CS1, a Phase 1/2 Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Patients with Myotonic Dystrophy Type 1 (DM1) (MARINA) (S23.006)
12. Filogeografía de mitogenomas indígenas de Uruguay
13. Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis
14. Inhibition of Calcium-Independent Phospholipase A 2 Prevents Arachidonic Acid Incorporation and Phospholipid Remodeling in P388D 1 Macrophages
15. Ancestría genética y estratificación social en Montevideo, Uruguay
16. v-Src induces Shc binding to tyrosine 63 in the cytoplasmic domain of the LDL receptor-related protein 1
17. mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin‐mediated amyloidosis
18. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis
19. Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis
20. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
21. Human Biology Genetic Admixture Analysis in the Population of Tacuarembó-Uruguay Using Alu Insertions Genetic Admixture Analysis in the Population of Tacuarembó-Uruguay Using Alu Insertions
22. Nonidentity of the alpha-neurotoxin binding sites on the nicotinic acetylcholine receptor revealed by modification in alpha-neurotoxin and receptor structures
23. Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling on P388D1 macrophages
24. Burden of hereditary transthyretin amyloidosis on quality of life
25. Responsiveness of Neuropathy Symptom and Change (NSC) Score Components in Inotersen Treatment of Hereditary Transthyretin Amyloidosis Polyneuropathy (P3.9-060)
26. Ancestría genética y estratificación social en Montevideo, Uruguay.
27. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
28. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial
29. Smart Somatotopic Quantitative Sensory Testing findings in hATTR with Polyneuropathy (P2.457)
30. Open Label Extension of the Phase 3 Study NEURO-TTR to Assess the Long-term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis (P1.324)
31. Safety and Efficacy of Inotersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (NEURO-TTR) (N2.001)
32. Burden of Hereditary Transthyretin Amyloidosis With Polyneuropathy in Patients Enrolled in the Phase 3 Study NEURO-TTR (P1.331)
33. Inotersen Improves Norfolk Quality of Life-Diabetic Neuropathy Measures in Patients With Hereditary Transthyretin Amyloidosis with Polyneuropathy in the Phase 3 Study NEURO-TTR (S5.006)
34. INOTERSEN IMPROVES QUALITY OF LIFE IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY AND CARDIOMYOPATHY: RESULTS OF THE PHASE 3 STUDY NEURO-TTR
35. Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells
36. Treatment of transthyretin cardiomyopathy with a TTR-specific antisense oligonucleotide (IONIS-TTRRx)
37. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides
38. Tu1724 In Vitro Study of the 2nd-Generation Antisense Oligonucleotide ISIS-TTRRX in Familial Amyloid Polyneuropathy-Specific Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cells
39. The transthyretin amyloidoses: advances in therapy
40. A Phase 3 Study to Evaluate ISIS-TTR Rx in Patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP): Study Design and Baseline Demographics (S50.006)
41. Breast cancer risk and genetic ancestry: a case–control study in Uruguay
42. The ISIS-TTRRx-CS2 phase 3 study in patients with familial amyloid polyneuropathy: Baseline results of the first 100 patients for the NIS, NIS+7 and mNIS+7 using different methods of scoring: identification of consistencies and key differences
43. A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy
44. Questioning the “Melting Pot”: Analysis ofAluInserts in Three Population Samples from Uruguay
45. Expression of eIF4E relevant biomarkers detected in circulating tumor cells from metastatic NSCLC and prostate cancer patients using antibody-independent ApoStream technology.
46. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy
47. Suppression of Vascular Endothelial Growth Factor-Mediated Endothelial Cell Protection by Survivin Targeting
48. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function
49. The Role of Antiapoptotic Bcl-2 Family Members in Endothelial Apoptosis Elucidated with Antisense Oligonucleotides
50. Identification of Pairwise Interactions in the α-Neurotoxin-Nicotinic Acetylcholine Receptor Complex through Double Mutant Cycles
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.